ADMA Biologics stock fell over 24% in after-hours trading on May 6, 2026, after the company withdrew its long-term financial guidance, citing evolving U.S. plasma products and immunoglobulin market competitive dynamics. The disclosure followed a prior Culper Research report alleging that ADMA’s reported growth was inflated by channel stuffing and misleading business practices related to Asceniv. Block & Leviton is investigating.
Contact our attorneys for a no-cost case evaluation.